Cargando…
Epigallocatechin-3-Gallate, an Active Green Tea Component to Support Anti-VEGFA Therapy in Wet Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is a largely incurable disease and an emerging problem in aging societies. It occurs in two forms, dry and wet (exudative, neovascular), which may cause legal blindness and sight loss. Currently, there is not any effective treatment for dry AMD. Meanwhile, repe...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10421466/ https://www.ncbi.nlm.nih.gov/pubmed/37571296 http://dx.doi.org/10.3390/nu15153358 |
_version_ | 1785088987364327424 |
---|---|
author | Blasiak, Janusz Chojnacki, Jan Szczepanska, Joanna Fila, Michal Chojnacki, Cezary Kaarniranta, Kai Pawlowska, Elzbieta |
author_facet | Blasiak, Janusz Chojnacki, Jan Szczepanska, Joanna Fila, Michal Chojnacki, Cezary Kaarniranta, Kai Pawlowska, Elzbieta |
author_sort | Blasiak, Janusz |
collection | PubMed |
description | Age-related macular degeneration (AMD) is a largely incurable disease and an emerging problem in aging societies. It occurs in two forms, dry and wet (exudative, neovascular), which may cause legal blindness and sight loss. Currently, there is not any effective treatment for dry AMD. Meanwhile, repeated intravitreal injections with antibodies effective against vascular endothelial growth factor A (VEGFA) slow down wet AMD progression but are not free from complications. (-)-Epigallocatechin-3-gallate (EGCG) is an active compound of green tea, which exerts many beneficial effects in the retinal pigment epithelium and the neural retina. It has been reported to downregulate the VEGFA gene by suppressing its activators. The inhibition of mitogen-activated protein kinases 1 and 3 (MAPK1 and MAPK3) may lie behind the antiangiogenic action of EGCG mediated by VEGFA. EGCG exerts protective effects against UV-induced damage to retinal cells and improves dysfunctional autophagy. EGCG may also interact with the mechanistic target rapamycin (MTOR) and unc-51-like autophagy activating kinase (ULK1) to modulate the interplay between autophagy and apoptosis. Several other studies report beneficial effects of EGCG on the retina that may be related to wet AMD. Therefore, controlled clinical trials are needed to verify whether diet supplementation with EGCG or green tea consumption may improve the results of anti-VEGFA therapy in wet AMD. |
format | Online Article Text |
id | pubmed-10421466 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104214662023-08-12 Epigallocatechin-3-Gallate, an Active Green Tea Component to Support Anti-VEGFA Therapy in Wet Age-Related Macular Degeneration Blasiak, Janusz Chojnacki, Jan Szczepanska, Joanna Fila, Michal Chojnacki, Cezary Kaarniranta, Kai Pawlowska, Elzbieta Nutrients Review Age-related macular degeneration (AMD) is a largely incurable disease and an emerging problem in aging societies. It occurs in two forms, dry and wet (exudative, neovascular), which may cause legal blindness and sight loss. Currently, there is not any effective treatment for dry AMD. Meanwhile, repeated intravitreal injections with antibodies effective against vascular endothelial growth factor A (VEGFA) slow down wet AMD progression but are not free from complications. (-)-Epigallocatechin-3-gallate (EGCG) is an active compound of green tea, which exerts many beneficial effects in the retinal pigment epithelium and the neural retina. It has been reported to downregulate the VEGFA gene by suppressing its activators. The inhibition of mitogen-activated protein kinases 1 and 3 (MAPK1 and MAPK3) may lie behind the antiangiogenic action of EGCG mediated by VEGFA. EGCG exerts protective effects against UV-induced damage to retinal cells and improves dysfunctional autophagy. EGCG may also interact with the mechanistic target rapamycin (MTOR) and unc-51-like autophagy activating kinase (ULK1) to modulate the interplay between autophagy and apoptosis. Several other studies report beneficial effects of EGCG on the retina that may be related to wet AMD. Therefore, controlled clinical trials are needed to verify whether diet supplementation with EGCG or green tea consumption may improve the results of anti-VEGFA therapy in wet AMD. MDPI 2023-07-28 /pmc/articles/PMC10421466/ /pubmed/37571296 http://dx.doi.org/10.3390/nu15153358 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Blasiak, Janusz Chojnacki, Jan Szczepanska, Joanna Fila, Michal Chojnacki, Cezary Kaarniranta, Kai Pawlowska, Elzbieta Epigallocatechin-3-Gallate, an Active Green Tea Component to Support Anti-VEGFA Therapy in Wet Age-Related Macular Degeneration |
title | Epigallocatechin-3-Gallate, an Active Green Tea Component to Support Anti-VEGFA Therapy in Wet Age-Related Macular Degeneration |
title_full | Epigallocatechin-3-Gallate, an Active Green Tea Component to Support Anti-VEGFA Therapy in Wet Age-Related Macular Degeneration |
title_fullStr | Epigallocatechin-3-Gallate, an Active Green Tea Component to Support Anti-VEGFA Therapy in Wet Age-Related Macular Degeneration |
title_full_unstemmed | Epigallocatechin-3-Gallate, an Active Green Tea Component to Support Anti-VEGFA Therapy in Wet Age-Related Macular Degeneration |
title_short | Epigallocatechin-3-Gallate, an Active Green Tea Component to Support Anti-VEGFA Therapy in Wet Age-Related Macular Degeneration |
title_sort | epigallocatechin-3-gallate, an active green tea component to support anti-vegfa therapy in wet age-related macular degeneration |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10421466/ https://www.ncbi.nlm.nih.gov/pubmed/37571296 http://dx.doi.org/10.3390/nu15153358 |
work_keys_str_mv | AT blasiakjanusz epigallocatechin3gallateanactivegreenteacomponenttosupportantivegfatherapyinwetagerelatedmaculardegeneration AT chojnackijan epigallocatechin3gallateanactivegreenteacomponenttosupportantivegfatherapyinwetagerelatedmaculardegeneration AT szczepanskajoanna epigallocatechin3gallateanactivegreenteacomponenttosupportantivegfatherapyinwetagerelatedmaculardegeneration AT filamichal epigallocatechin3gallateanactivegreenteacomponenttosupportantivegfatherapyinwetagerelatedmaculardegeneration AT chojnackicezary epigallocatechin3gallateanactivegreenteacomponenttosupportantivegfatherapyinwetagerelatedmaculardegeneration AT kaarnirantakai epigallocatechin3gallateanactivegreenteacomponenttosupportantivegfatherapyinwetagerelatedmaculardegeneration AT pawlowskaelzbieta epigallocatechin3gallateanactivegreenteacomponenttosupportantivegfatherapyinwetagerelatedmaculardegeneration |